The #FDA has started a #priorityreview of #AstraZeneca's IL-33-targeting antibody #tozorakimab for chronic obstructive pulmonary disease (#COPD), setting up a decision on the would-be blockbuster in the first quarter of 2027.
@pharmaphorum.bsky.social